Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women with metastatic (Stage IV) breast cancer, or with locally advanced breast cancer (Stages IIIA \> 10 cm, or Stages IIIB and IIIC) that did not respond to first-line anthracycline-based chemotherapy, for whom docetaxel is a recommended therapy~* Presence of measurable or evaluable disease~* Adequate organ function~* Ability to swallow intact study drug capsules~* Zubrod Performance Status of 0-1 with at least a 3 month life expectancy~* Appropriate time must have elapsed since prior anti-neoplastic therapy with resolution of acute toxicity~Exclusion Criteria:~* Concurrent treatment with hormonal therapy intended to treat cancer~* Radiotherapy within 7 days prior to first dose~* Symptomatic central nervous system, and/or epidural metastases or symptomatic carcinomatous meningitis or with radiation treatment completed within the past 8 weeks~* Serious comorbid illness which will limit the ability of the patient to safely receive anticancer treatment~* Patients who are pregnant or nursing~* Confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-0752, Docetaxel, Pegfilgrastim (Type: EXPERIMENTAL): MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752

Based on this trial design, predict the completion outcome and termination type (if applicable).